

Beat W Scá,§afer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/472948/publications.pdf>

Version: 2024-02-01

126
papers

7,780
citations

41339

49
h-index

56717

83
g-index

129
all docs

129
docs citations

129
times ranked

10453
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization. <i>Neoplasia</i> , 2022, 27, 100784.	5.3	3
2	CRISPR activation screen identifies TGF β 2-associated PEG10 as a crucial tumor suppressor in Ewing sarcoma. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
3	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. <i>European Journal of Cancer</i> , 2022, 172, 367-386.	2.8	19
4	Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies. <i>Modern Pathology</i> , 2021, 34, 748-757.	5.5	19
5	Paracrine Placental Growth Factor Signaling in Response to Ionizing Radiation Is p53-Dependent and Contributes to Radioresistance. <i>Molecular Cancer Research</i> , 2021, 19, 1051-1062.	3.4	3
6	Fenretinide Acts as Potent Radiosensitizer for Treatment of Rhabdomyosarcoma Cells. <i>Frontiers in Oncology</i> , 2021, 11, 664462.	2.8	2
7	Negative correlation of single-cell <i>PAX3:FOXO1</i> expression with tumorigenicity in rhabdomyosarcoma. <i>Life Science Alliance</i> , 2021, 4, e202001002.	2.8	4
8	High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma. <i>Genes</i> , 2021, 12, 1373.	2.4	3
9	A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors. <i>Neoplasia</i> , 2021, 23, 929-938.	5.3	2
10	YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells. <i>Oncogenesis</i> , 2021, 10, 2.	4.9	32
11	BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma. <i>Nature Communications</i> , 2021, 12, 6924.	12.8	25
12	Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. <i>Cancer Research</i> , 2020, 80, 832-842.	0.9	31
13	Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma. <i>Cancers</i> , 2020, 12, 3313.	3.7	17
14	Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity. <i>Nature Communications</i> , 2020, 11, 4629.	12.8	32
15	Miswired Enhancer Logic Drives a Cancer of the Muscle Lineage. <i>IScience</i> , 2020, 23, 101103.	4.1	26
16	Fenretinide induces a new form of dynamin-dependent cell death in pediatric sarcoma. <i>Cell Death and Differentiation</i> , 2020, 27, 2500-2516.	11.2	11
17	Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma. <i>Cancers</i> , 2020, 12, 304.	3.7	13
18	NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency. <i>ELife</i> , 2020, 9, .	6.0	36

#	ARTICLE	IF	CITATIONS
19	USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth. <i>Scientific Reports</i> , 2019, 9, 951.	3.3	28
20	A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas. <i>Frontiers in Oncology</i> , 2019, 9, 1271.	2.8	12
21	PAX3-FOXO1: Zooming in on an "undruggable" target. <i>Seminars in Cancer Biology</i> , 2018, 50, 115-123.	9.6	39
22	Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000). <i>Journal of Clinical Oncology</i> , 2018, 36, 244-253.	1.6	71
23	Duxblng Stem Cells Meet Tumorigenesis. <i>Cell Stem Cell</i> , 2018, 23, 773-774.	11.1	0
24	The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion. <i>PLoS ONE</i> , 2016, 11, e0161396.	2.5	16
25	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. <i>Oncotarget</i> , 2016, 7, 8613-8624.	1.8	55
26	Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue. <i>Journal of Biological Chemistry</i> , 2016, 291, 26922-26933.	3.4	23
27	Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 4237-4249.	8.2	46
28	The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells. <i>Oncotarget</i> , 2016, 7, 76743-76755.	1.8	5
29	Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. <i>Oncotarget</i> , 2016, 7, 1451-1463.	1.8	48
30	Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma. <i>Current Drug Targets</i> , 2016, 17, 1228-1234.	2.1	2
31	Unpeaceful roles of mutant PAX proteins in cancer. <i>Seminars in Cell and Developmental Biology</i> , 2015, 44, 126-134.	5.0	14
32	PLK1 Phosphorylates PAX3-FOXO1, the Inhibition of Which Triggers Regression of Alveolar Rhabdomyosarcoma. <i>Cancer Research</i> , 2015, 75, 98-110.	0.9	36
33	PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1. <i>Oncotarget</i> , 2015, 6, 28895-28910.	1.8	21
34	FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells. <i>International Journal of Cancer</i> , 2014, 135, 1543-1552.	5.1	21
35	Rhabdomyosarcoma: Current Challenges and Their Implications for Developing Therapies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a025650-a025650.	6.2	60
36	Cancer Stem Cells in Pediatric Sarcomas. <i>Stem Cells and Cancer Stem Cells</i> , 2014, , 111-126.	0.1	0

#	ARTICLE	IF	CITATIONS
37	ESF-EMBO Symposium "Molecular Biology and Innovative Therapies in Sarcomas of Childhood and Adolescence" Sept 29-Oct 4, Polonia Castle Pultusk, Poland. <i>Frontiers in Oncology</i> , 2013, 3, 142.	2.8	2
38	Cell-Based Small-Molecule Compound Screen Identifies Fenretinide as Potential Therapeutic for Translocation-Positive Rhabdomyosarcoma. <i>PLoS ONE</i> , 2013, 8, e55072.	2.5	20
39	The First European Interdisciplinary Ewing Sarcoma Research Summit. <i>Frontiers in Oncology</i> , 2012, 2, 54.	2.8	32
40	Preferred analysis methods for single genomic regions in RNA sequencing revealed by processing the shape of coverage. <i>Nucleic Acids Research</i> , 2012, 40, e63-e63.	14.5	4
41	Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma. <i>International Journal of Cancer</i> , 2012, 131, 2153-2164.	5.1	65
42	CD133 Positive Embryonal Rhabdomyosarcoma Stem-Like Cell Population Is Enriched in Rhabdospheres. <i>PLoS ONE</i> , 2011, 6, e19506.	2.5	111
43	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. <i>Blood</i> , 2011, 118, 2077-2084.	1.4	370
44	Generation of a novel <i>rtTA</i> transgenic mouse to induce time-controlled, tissue-specific alterations in <i>Pax2</i> -expressing cells. <i>Genesis</i> , 2011, 49, 797-802.	1.6	6
45	Targets for cancer therapy in childhood sarcomas. <i>Cancer Treatment Reviews</i> , 2010, 36, 318-327.	7.7	93
46	Multidisciplinary management of childhood sarcoma: time to expand. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1163-1166.	2.4	0
47	Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. <i>Journal of Clinical Investigation</i> , 2010, 120, 1310-1323.	8.2	287
48	Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model. <i>PLoS ONE</i> , 2010, 5, e10445.	2.5	31
49	Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1838-1845.	4.1	46
50	Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide <i>LyP1</i> . <i>International Journal of Cancer</i> , 2009, 124, 2026-2032.	5.1	28
51	Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2 ¹ as biomarkers for rhabdomyosarcoma diagnostics. <i>Histopathology</i> , 2009, 54, 873-879.	2.9	40
52	Phosphorylation Regulates Transcriptional Activity of PAX3/FKHR and Reveals Novel Therapeutic Possibilities. <i>Cancer Research</i> , 2008, 68, 3767-3776.	0.9	49
53	Anemia and survival in childhood acute lymphoblastic leukemia. <i>Haematologica</i> , 2008, 93, 1652-1657.	3.5	14
54	Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. <i>Blood</i> , 2007, 110, 2084-2091.	1.4	53

#	ARTICLE	IF	CITATIONS
55	Prediction of chromosomal aneuploidy from gene expression data. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 75-86.	2.8	45
56	Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors. <i>Cancer Genetics and Cytogenetics</i> , 2007, 172, 61-65.	1.0	23
57	S100A1-deficient male mice exhibit increased exploratory activity and reduced anxiety-related responses. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2006, 1763, 1307-1319.	4.1	24
58	Subtype and Prognostic Classification of Rhabdomyosarcoma by Immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2006, 24, 816-822.	1.6	133
59	Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2005, 105, 821-826.	1.4	142
60	Clonal expansion of a new MLL rearrangement in the absence of leukemia. <i>Blood</i> , 2005, 105, 4151-4152.	1.4	20
61	Four and Half Lim Protein 2 (FHL2) Stimulates Osteoblast Differentiation. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 17-28.	2.8	43
62	The Calcium-binding Protein S100A2 Interacts with p53 and Modulates Its Transcriptional Activity. <i>Journal of Biological Chemistry</i> , 2005, 280, 29186-29193.	3.4	124
63	The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. <i>Carcinogenesis</i> , 2004, 25, 1839-1846.	2.8	57
64	Gene Expression Signatures Identify Rhabdomyosarcoma Subtypes and Detect a Novel t(2;2)(q35;p23) Translocation Fusing PAX3 to NCOA1. <i>Cancer Research</i> , 2004, 64, 5539-5545.	0.9	224
65	Cancer predisposition in mice deficient for the metastasis-associated Mts1(S100A4) gene. <i>Oncogene</i> , 2004, 23, 3670-3680.	5.9	59
66	Correlation of S100A4 expression with invasion and metastasis in oral squamous cell carcinoma. <i>Oral Oncology</i> , 2004, 40, 496-500.	1.5	33
67	S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2004, 316, 949-959.	2.1	97
68	Gene expression profiles and risk stratification in childhood acute lymphoblastic leukemia. <i>Haematologica</i> , 2004, 89, 801-8.	3.5	17
69	Ca ²⁺ -dependent interaction of S100A1 with the sarcoplasmic reticulum Ca ²⁺ -ATPase2a and phospholamban in the human heart. <i>Biochemical and Biophysical Research Communications</i> , 2003, 306, 550-557.	2.1	74
70	Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 375-381.	2.1	130
71	The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. <i>Genes and Development</i> , 2003, 17, 2950-2965.	5.9	132
72	Telomerase Activity in Cell Lines of Pediatric Soft Tissue Sarcomas. <i>Pediatric Research</i> , 2003, 54, 718-723.	2.3	14

#	ARTICLE	IF	CITATIONS
73	The Family of S100 Cell Signaling Proteins. , 2003, , 87-93.		4
74	Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. Journal of Cell Science, 2002, 115, 4925-4936.	2.0	230
75	The LIM-only Protein DRAL/FHL2 Interacts with and Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. Journal of Biological Chemistry, 2002, 277, 37045-37053.	3.4	67
76	Molecular Cloning and Characterization of the Human S100A14 Gene Encoding a Novel Member of the S100 Family. Genomics, 2002, 79, 513-522.	2.9	76
77	S100 proteins structure functions and pathology. Frontiers in Bioscience - Landmark, 2002, 7, d1356-1368.	3.0	327
78	S100A13 and S100A6 exhibit distinct translocation pathways in endothelial cells. Journal of Cell Science, 2002, 115, 3149-58.	2.0	35
79	Structural Insight into Human Zn ²⁺ -Bound S100A2 from NMR and Homology Modeling. Biochemical and Biophysical Research Communications, 2001, 288, 462-467.	2.1	19
80	S100A2, a Putative Tumor Suppressor Gene, Regulates In Vitro Squamous Cell Carcinoma Migration. Laboratory Investigation, 2001, 81, 599-612.	3.7	83
81	Immunolocalization of the calcium binding S100A1, S100A5 and S100A6 proteins in the dog cochlea during postnatal development. Developmental Brain Research, 2001, 126, 191-199.	1.7	53
82	Prognostic significance of the Ca ²⁺ binding protein S100A2 in laryngeal squamous-cell carcinoma. International Journal of Cancer, 2000, 89, 345-349.	5.1	58
83	Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene, 2000, 19, 2921-2929.	5.9	95
84	Concomitant Amplification and Expression of PAX7-FKHR and MYCN in a Human Rhabdomyosarcoma Cell Line Carrying a Cryptic t(1;13)(p36;q14). Cancer Genetics and Cytogenetics, 2000, 121, 139-145.	1.0	20
85	S100 proteins in Corpora Amylacea from normal human brain ¹¹ Published on the World Wide Web on 5 May 2000.. Brain Research, 2000, 867, 280-288.	2.2	70
86	Inv(11)(p13p15) and Myf-3(MyoD1) in a Malignant Extrarenal Rhabdoid Tumor of a Premature Newborn. Pediatric Research, 2000, 48, 463-467.	2.3	17
87	Dral Is a P53-Responsive Gene Whose Four and a Half Lim Domain Protein Product Induces Apoptosis. Journal of Cell Biology, 2000, 151, 495-506.	5.2	93
88	Cloning and Characterization of the Human PAX7 Promoter. Biological Chemistry, 2000, 381, 331-5.	2.5	10
89	S100A13. Journal of Biological Chemistry, 2000, 275, 8686-8694.	3.4	49
90	Brain S100A5 Is a Novel Calcium-, Zinc-, and Copper Ion-binding Protein of the EF-hand Superfamily. Journal of Biological Chemistry, 2000, 275, 30623-30630.	3.4	90

#	ARTICLE	IF	CITATIONS
91	S100A1, a New Marker for Acute Myocardial Ischemia. <i>Biochemical and Biophysical Research Communications</i> , 2000, 274, 865-871.	2.1	55
92	Transcriptional regulation of S100A1 and expression during mouse heart development. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2000, 1498, 207-219.	4.1	41
93	Subcellular distribution of S100 proteins in tumor cells and their relocation in response to calcium activation. <i>Histochemistry and Cell Biology</i> , 1999, 111, 453-459.	1.7	68
94	Distribution of a specific calcium-binding protein of the S100 protein family, S100A6 (calcylin), in subpopulations of neurons and glial cells of the adult rat nervous system. , 1999, 404, 235-257.		60
95	Transcriptional activation of the human S100A2 promoter by wild-type p53. <i>FEBS Letters</i> , 1999, 445, 265-268.	2.8	63
96	Supratentorial Pilocytic Astrocytomas, Astrocytomas, Anaplastic Astrocytomas and Glioblastomas are Characterized by a Differential Expression of S100 Proteins. <i>Brain Pathology</i> , 1999, 9, 1-19.	4.1	82
97	Distribution of a specific calcium-binding protein of the S100 protein family, S100A6 (calcylin), in subpopulations of neurons and glial cells of the adult rat nervous system. <i>Journal of Comparative Neurology</i> , 1999, 404, 235-257.	1.6	1
98	Immunohistochemical localization of S100A1 and S100A6 in postnatally developing salivary glands of rats. <i>Histochemistry and Cell Biology</i> , 1998, 110, 579-587.	1.7	15
99	Localization of Ca ²⁺ -binding S100 proteins in epithelial tumours of the skin. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1998, 432, 53-59.	2.8	65
100	Clustered organization of S100 genes in human and mouse. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1998, 1448, 254-263.	4.1	74
101	Binding of Ca ²⁺ and Zn ²⁺ to Human Nuclear S100A2 and Mutant Proteins. <i>Journal of Biological Chemistry</i> , 1998, 273, 18826-18834.	3.4	46
102	Rapid Molecular Diagnosis of Erythropoietic Protoporphyrin among Swiss Patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 763-5.	2.3	5
103	Subtractive Cloning and Characterization of DRAL, a Novel LIM-Domain Protein Down-Regulated in Rhabdomyosarcoma. <i>DNA and Cell Biology</i> , 1997, 16, 433-442.	1.9	113
104	Novel Ca ²⁺ -binding S100 Proteins, Glial Fibrillary Acidic Protein and Tenascin in Chondro-osseous Tumors.. <i>Acta Histochemica Et Cytochemica</i> , 1997, 30, 445-453.	1.6	2
105	Selective association of S100A61According to the new nomenclature of S100 proteins [23].1 (calcylin)-immunoreactive astrocytes with the tangential migration pathway of subventricular zone cells in the rat. <i>Brain Research</i> , 1997, 778, 388-392.	2.2	22
106	Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. <i>Cell Calcium</i> , 1997, 22, 243-254.	2.4	108
107	Human recombinant alpha-parvalbumin and nine mutants with individually inactivated calcium- and magnesium-binding sites: biochemical and immunological properties. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1996, 1313, 179-186.	4.1	21
108	Altered expression of the Ca ²⁺ -binding protein S100A1 in human cardiomyopathy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1996, 1313, 253-257.	4.1	149

#	ARTICLE	IF	CITATIONS
109	Identification of Novel DNA Binding Sites Recognized by the Transcription Factor mPOU (POU6F1). <i>Biochemical and Biophysical Research Communications</i> , 1996, 220, 274-279.	2.1	13
110	Characterization of the Human and Mouse cDNAs Coding for S100A13, a New Member of the S100 Protein Family. <i>Biochemical and Biophysical Research Communications</i> , 1996, 227, 594-599.	2.1	75
111	Î±-Parvalbumin reduces depolarization-induced elevations of cytosolic free calcium in human neuroblastoma cells. <i>Cell Calcium</i> , 1996, 19, 527-533.	2.4	14
112	Characterization of the human S100A12 (calgranulin C, p6, CAAF1, CGRP) gene, a new member of the S100 gene cluster on chromosome 1q21. <i>Cell Calcium</i> , 1996, 20, 459-464.	2.4	78
113	The S100 family of EF-hand calcium-binding proteins: functions and pathology. <i>Trends in Biochemical Sciences</i> , 1996, 21, 134-140.	7.5	585
114	Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. , 1996, 66, 571-577.		71
115	Expression pattern of S100 calcium-binding proteins in human tumors. , 1996, 68, 325-332.		207
116	Immunohistochemical evaluation of the Ca ²⁺ -binding S-100 proteins S-100A1, S-100A2, S-100A4, S-100A6 and S-100B in salivary gland tumors. <i>Journal of Oral Pathology and Medicine</i> , 1996, 25, 547-555.	2.7	42
117	Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. <i>International Journal of Cancer</i> , 1996, 66, 571-577.	5.1	1
118	Human ferrochelatase: a novel mutation in patients with erythropoietic protoporphyria and an isoform caused by alternative splicing. <i>Human Genetics</i> , 1995, 95, 391-6.	3.8	15
119	Purification and Cation Binding Properties of the Recombinant Human S100 Calcium-binding Protein A3, an EF-hand Motif Protein with High Affinity for Zinc. <i>Journal of Biological Chemistry</i> , 1995, 270, 21056-21061.	3.4	63
120	Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. <i>Genomics</i> , 1995, 25, 638-643.	2.9	321
121	Molecular cloning and characterization of a human PAX-7 cDNA expressed in normal and neoplastic myocytes. <i>Nucleic Acids Research</i> , 1994, 22, 4574-4582.	14.5	89
122	Expression of Ca ²⁺ -binding proteins of the S100 family in malignant human breast-cancer cell lines and biopsy samples. <i>International Journal of Cancer</i> , 1994, 57, 684-690.	5.1	133
123	A human POU domain gene, mPOU, is expressed in developing brain and specific adult tissues. <i>FEBS Journal</i> , 1994, 220, 753-762.	0.2	24
124	Expression of intracellular calcium-binding proteins in cultured skin fibroblasts from Alzheimer and normal aged donors. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1994, 1223, 391-397.	4.1	9
125	Human alpha and beta parvalbumins. Structure and tissue-specific expression. <i>FEBS Journal</i> , 1993, 215, 719-727.	0.2	72
126	Effect of cell history on response to helixâ€“loopâ€“helix family of myogenic regulators. <i>Nature</i> , 1990, 344, 454-458.	27.8	163